RAC1 P29S confers resistance to BRAF inhibitors through the SRF/MRTF signaling pathway, indicating that targeted SRF/MRTF therapy may overcome BRAF inhibitor resistance in melanoma patients with RAC1P29S mutations. The gene discussed is SRF; the disease is melanoma.